Glenn J Hanna1, Christie J Lau2, Umair Mahmood3, Julianna G Supplee2, Abhishek R Mogili2, Robert I Haddad3, Pasi A Jänne4, Cloud P Paweletz2. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: glenn_hanna@dfci.harvard.edu. 2. Robert and Renée Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, USA. 3. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Robert and Renée Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, USA.
Abstract
OBJECTIVES: Quantifying tumor DNA in tissue and circulating in blood permits high-quality molecular monitoring to detect and track cancer progression. Evaluating tumor DNA in both blood and saliva in human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) could provide a non-invasive and clinically actionable method for real-time disease detection. METHODS: We previously validated an ultrasensitive droplet-digital (dd)PCR assay targeting the dominant high-risk HPV subtypes causally linked to OPC. Here we enrolled an observational cohort to evaluate the predictive and prognostic potential of paired plasma-salivary tumor DNA among 21 patients with advanced HPV+OPC. RESULTS: In patients with recurrent, persistent locoregional (LR) disease, median baseline normalized salivary HPV DNA was 10.9 copies/ng total DNA, nearly 20x higher compared with those with distant disease only (p = 0.01). A cutoff of 5 copies/ng yielded 87% sensitivity and 67% specificity for accurately predicting LR disease. Total tumor burden among those with LR disease strongly correlated with salivary HPV DNA levels (R = 0.83, p = 0.02). The rise and fall of salivary HPV DNA predicted treatment failure and response, respectively, in all patients with LR disease, and predated imaging findings. Among paired salivary-plasma (cell-free) cfDNA samples, only higher plasma HPV cfDNA levels were associated with poor outcomes (p < 0.01), suggesting that each bodily fluid provides unique information about HPV disease status. CONCLUSIONS: Salivary HPV DNA provides valuable information about tumor burden and predicts treatment response in advanced HPV+OPC. Paired blood-saliva samples could be used to monitor HPV DNA with broad applications to inform diagnosis, prognosis, and surveillance in HPV-associated diseases.
OBJECTIVES: Quantifying tumor DNA in tissue and circulating in blood permits high-quality molecular monitoring to detect and track cancer progression. Evaluating tumor DNA in both blood and saliva in human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) could provide a non-invasive and clinically actionable method for real-time disease detection. METHODS: We previously validated an ultrasensitive droplet-digital (dd)PCR assay targeting the dominant high-risk HPV subtypes causally linked to OPC. Here we enrolled an observational cohort to evaluate the predictive and prognostic potential of paired plasma-salivary tumor DNA among 21 patients with advanced HPV+OPC. RESULTS: In patients with recurrent, persistent locoregional (LR) disease, median baseline normalized salivary HPV DNA was 10.9 copies/ng total DNA, nearly 20x higher compared with those with distant disease only (p = 0.01). A cutoff of 5 copies/ng yielded 87% sensitivity and 67% specificity for accurately predicting LR disease. Total tumor burden among those with LR disease strongly correlated with salivary HPV DNA levels (R = 0.83, p = 0.02). The rise and fall of salivary HPV DNA predicted treatment failure and response, respectively, in all patients with LR disease, and predated imaging findings. Among paired salivary-plasma (cell-free) cfDNA samples, only higher plasma HPV cfDNA levels were associated with poor outcomes (p < 0.01), suggesting that each bodily fluid provides unique information about HPV disease status. CONCLUSIONS: Salivary HPV DNA provides valuable information about tumor burden and predicts treatment response in advanced HPV+OPC. Paired blood-saliva samples could be used to monitor HPV DNA with broad applications to inform diagnosis, prognosis, and surveillance in HPV-associated diseases.
Authors: Giulia Siravegna; Connor J O'Boyle; Jeremy D Richmon; Daniel L Faden; Shohreh Varmeh; Natalia Queenan; Alexa Michel; Jarrod Stein; Julia Thierauf; Peter M Sadow; William C Faquin; Simon K Perry; Adam Z Bard; Wei Wang; Daniel G Deschler; Kevin S Emerick; Mark A Varvares; Jong C Park; John R Clark; Annie W Chan; Vanessa Carlota Andreu Arasa; Osamu Sakai; Jochen Lennerz; Ryan B Corcoran; Lori J Wirth; Derrick T Lin; A John Iafrate Journal: Clin Cancer Res Date: 2022-02-15 Impact factor: 13.801
Authors: Sarah M Dermody; Catherine T Haring; Chandan Bhambhani; Muneesh Tewari; J Chad Brenner; Paul L Swiecicki Journal: Curr Treat Options Oncol Date: 2021-02-08
Authors: Susanne Flach; Karen Howarth; Sophie Hackinger; Christodoulos Pipinikas; Pete Ellis; Kirsten McLay; Giovanni Marsico; Tim Forshew; Christoph Walz; Christoph A Reichel; Olivier Gires; Martin Canis; Philipp Baumeister Journal: Br J Cancer Date: 2022-02-07 Impact factor: 9.075